Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Liabilities and Shareholders Equity (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $165.1 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Liabilities and Shareholders Equity fell 28.5% year-over-year to $165.1 million, compared with a TTM value of $553.0 million through Dec 2024, down 27.96%, and an annual FY2023 reading of $220.6 million, up 36.44% over the prior year.
  • Liabilities and Shareholders Equity was $165.1 million for Q3 2024 at Oramed Pharmaceuticals, down from $184.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $230.9 million in Q3 2023 and bottomed at $156.3 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $180.1 million, with a median of $165.1 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 40.41% in 2023, then dropped 28.5% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $161.6 million in 2022, then surged by 36.44% to $220.6 million in 2023, then dropped by 25.15% to $165.1 million in 2024.
  • Business Quant data shows Liabilities and Shareholders Equity for ORMP at $165.1 million in Q3 2024, $184.2 million in Q2 2024, and $203.7 million in Q1 2024.